Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Stock Price & Analysis
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) fell 3.34% to USD 2.89 as of July 25, 2026 at 08:22 UTC, according to Nexqual real-time market data.
SHPH last closed at USD 2.99; the session ranged USD 2.78–2.93 on volume of 77,463 shares. Market capitalization is $1.69M, with a 52-week range of USD 2.71–55.9 (NCM). Source: Nexqual, July 25, 2026 at 08:22 UTC.
Key Statistics (as of July 25, 2026 at 08:22 UTC)
| Price | USD 2.89 |
|---|---|
| Change | ▼ 3.34% (down) |
| Previous Close | USD 2.99 |
| Open | USD 2.93 |
| Day Range | USD 2.78 – 2.93 |
| 52-Week Range | USD 2.71 – 55.9 |
| Volume | 77,463 shares |
| Market Cap | $1.69M |
| Exchange | NCM |
Technical Analysis (SHPH)
Nexqual's technical model rates SHPH "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 08:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.01 (neutral) |
| vs SMA50 | Below (USD 4.34) |
| MACD | -0.38 (negative) |
Analyst Ratings (SHPH)
Wall Street analysts rate SHPH "None", per Nexqual as of July 25, 2026 at 08:22 UTC.
| Consensus Rating | None |
|---|
Earnings (SHPH)
Source: Nexqual, July 25, 2026 at 08:22 UTC.
Financials & Fundamentals (SHPH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -326.36% |
| Debt / Equity | 6.4 |
| Current Ratio | 0.3 |
| Total Cash | $1.09M |
| Total Debt | $214,013 |
| Free Cash Flow | $740,942 |
Source: Nexqual, July 25, 2026 at 08:22 UTC.
Financial Health Score (SHPH)
Nexqual rates Shuttle Pharmaceuticals Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Solid — $1M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -326%, ROA -81.7% |
Ownership (SHPH)
| Insider Ownership | +6.30% |
|---|---|
| Institutional Ownership | +12.88% |
| Shares Outstanding | 585,129 |
| Float | 582,385 |
| Short % of Float | +74.36% |
Source: Nexqual, July 25, 2026 at 08:22 UTC.
Leadership (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. is led by Christopher Robert Cooper BBA (age 55), Interim CEO & Director, per Nexqual as of July 25, 2026 at 08:22 UTC.
| Interim CEO & Director | Christopher Robert Cooper BBA (age 55) |
|---|
Major Backers & Investors (SHPH)
Notable institutional backers of Shuttle Pharmaceuticals Holdings, Inc. include Ikarian Capital, LLC, Fidelity, Boothbay Fund Management, LLC, according to Nexqual as of July 25, 2026 at 08:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 1.08% |
| Fidelity | 0.59% |
| Boothbay Fund Management, LLC | 0.32% |
| Virtu Financial LLC | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.73% |
Source: Nexqual, July 25, 2026 at 08:22 UTC.
From Shuttle Pharmaceuticals Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- The platform will increasingly support insights that connect chemical properties with biological implications, which creates a more complete, end-to-end picture for early research teams.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIAF | bioAffinity Technologies, Inc. | USD 0.66 | ▼ 6.79% |
| ATXG | Addentax Group Corp. | USD 3.7 | ▼ 2.63% |
| VRAX | Virax Biolabs Group Limited | USD 3.19 | ▼ 12.36% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:22 UTC. This page is informational and not investment advice.